evipedia.aidev
← Back

Riboflavin for Health & Longevity

Evidence Review created on 08/15/2026 using AI4L / Grok 4

Also known as: Vitamin B2, Riboflavine, Lactoflavin, Vitamin G

Motivation

Riboflavin, also called vitamin B2, is a water-soluble vitamin the body uses to turn food into cellular energy and cannot store in large amounts. Health-optimizing adults still look at extra riboflavin because the same vitamin sits inside the cell’s energy machinery and because migraine clinics use daily amounts far above the ordinary dietary need.

Frank shortage is now uncommon where flour is fortified. What remains interesting is the gap between that tiny daily need — just over a milligram — and the 400-milligram amounts used for migraine prevention, plus the observation that a common inherited change in a folate-handling enzyme makes some adults more dependent on this vitamin for blood-pressure control.

This review gathers published clinical trials, research reviews, and laboratory work on oral riboflavin as a health and longevity intervention. It examines claimed benefits, safety at ordinary and high doses, who appears to respond, and how practitioners actually use the vitamin.

Benefits - Risks - Protocol - Conclusion

High-level overviews of riboflavin as a migraine, mitochondrial, and methylation nutrient.

Single-author narrative mapping food sources, deficiency signs, iron handling, and the then-emerging homocysteine story without pooling trials.

Neurology narrative covering migraine, riboflavin-transporter disease, and flavoprotein defects, and stating the American Academy of Neurology Level B rating from a society whose members bill visits and prescriptions, not this vitamin.

Society briefing that names 400 mg riboflavin as a first-step nutraceutical for migraine and ties that dose to mitochondrial energy charge. Society members bill visits and prescriptions, not this vitamin.

Three high-level overviews met the inclusion bar. Rhonda Patrick’s Q&A #11 and Aliquot #134 mention riboflavin only inside a broader migraine or homocysteine discussion, not as a standalone overview. Peter Attia’s AMA #69 discusses B vitamins as a class, not riboflavin in depth. No dedicated Huberman Lab episode, Chris Kresser article, or Lifespan.io review of riboflavin was found; Lifespan.io mentions it only as a glutathione-reductase cofactor. Life Extension magazine pieces fold riboflavin into broader magnesium or multi-nutrient migraine articles rather than a dedicated overview.

Grokipedia

Compact reference covering chemistry, deficiency, transporters, and clinical uses, useful as a map before the trial literature.

Examine

Examine’s human-data page condenses migraine, blood pressure, anemia, and safety findings with dose context.

ConsumerLab

Independent product testing, absorption note (intake with a large meal), and approved standalone riboflavin products, including riboflavin 5’-phosphate.

Systematic Reviews

Pooled human reviews of riboflavin for migraine, blood pressure, the EGRac riboflavin-status test (erythrocyte glutathione reductase activation coefficient), methylenetetrahydrofolate reductase (MTHFR, the folate-remethylation enzyme), and colorectal cancer.

Nine trials (673 people) found 400 mg daily for three months cut migraine days, duration, frequency, and pain.

Eleven trials: consistent adult benefit, mixed pediatric results, and generally mild adverse events.

Four randomized controlled trials (RCTs), 374 people: blood-pressure effect very uncertain; little difference in adverse events versus control.

Eighteen supplementation studies; EGRac tracks intake, while homocysteine falls mainly in MTHFR 677TT.

Fourteen intake studies; relative colorectal-cancer risk 0.87, with a 10% drop near 5 mg per day.

Mechanism of Action

Riboflavin is converted inside cells to flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), the cofactors for more than ninety flavoproteins. Those enzymes run mitochondrial electron transport at complexes I and II, fatty-acid oxidation, and glutathione reductase, which recycles oxidized glutathione back to its reduced antioxidant form.

A second, genotype-specific role uses FAD to stabilize methylenetetrahydrofolate reductase (MTHFR, the folate-remethylation enzyme). The common MTHFR C677T variant (cytosine replaced by thymine at position 677) yields an enzyme that sheds FAD more easily; extra riboflavin can restabilize it and restore remethylation of homocysteine.

Intestinal uptake is saturable through riboflavin transporters RFVT1, RFVT2, and RFVT3 (encoded by the SLC52A1, SLC52A2, and SLC52A3 transporter genes). Plasma half-life of free riboflavin is about one to two hours; tissue FAD turns over more slowly. Excess appears in urine as a bright yellow pigment. Activation uses riboflavin kinase then FAD synthase, not cytochrome P450 enzymes. Selectivity is that of a vitamin cofactor, not a receptor ligand. Stores concentrate in liver, kidney, and heart.

Competing accounts of the migraine effect emphasize restored mitochondrial ATP (adenosine triphosphate, the cell’s energy currency) production versus downstream redox effects; both sit on the same cofactor biochemistry.

Historical Context & Evolution

Warburg, Kuhn, György and coworkers isolated the yellow growth factor from milk and egg white in the 1930s and named it riboflavin. It entered nutrition tables as vitamin B2 (briefly also called vitamin G). Flour and cereal fortification from the 1940s largely removed frank ariboflavinosis (sore throat, cracked lips, inflamed tongue, oily scaly skin, and anemia) from fortified countries.

Two later research lines moved the vitamin from deficiency disease to optimization. Schoenen’s group, working from phosphorus magnetic-resonance signs of low brain energy charge in migraine, tested 400 mg daily and reported fewer attacks. Independently, McNulty, Scott and colleagues showed that riboflavin restabilizes variant MTHFR and can lower homocysteine and blood pressure in people with the 677TT genotype.

Ophthalmology developed a different use: topical riboflavin plus ultraviolet-A light to cross-link corneal collagen in keratoconus (a progressive thinning and conical bulge of the cornea). That is a local photochemical procedure, not an oral longevity protocol.

Opinion has not closed. Adult migraine guidelines rate riboflavin as probably effective, while a 2025 Cochrane review judged blood-pressure evidence very uncertain. Both the positive Ulster trials and that cautious synthesis remain available to weigh.

Expected Benefits

High 🟩 🟩 🟩

Reduction of Migraine Attack Frequency

High-dose riboflavin is used to restore mitochondrial energy in migraine. A 2022 meta-analysis of nine trials (673 people) found fewer days, shorter attacks, and lower pain at 400 mg daily (Chen et al., 2022). Schoenen reported a 59% versus 15% 50%-responder rate (number needed to treat, NNT, 2.3) (Schoenen et al., 1998). The 2012 American Academy of Neurology / American Headache Society Level B rating is from societies that bill visits and prescriptions, not this vitamin; pediatric trials are mixed (Holland et al., 2012).

Magnitude: 59% versus 15% of adults achieved a 50% or greater drop in headache days at 400 mg daily for 3 months (NNT 2.3); pooled analyses also reduced days, duration, frequency, and pain.

Medium 🟩 🟩

Lowering of Homocysteine in MTHFR 677TT Genotype

In people homozygous for MTHFR C677T, 1.6 mg riboflavin daily for 12 weeks lowered plasma homocysteine 22% (16.1 to 12.5 µmol/L), and 40% when baseline riboflavin status was poor (McNulty et al., 2006). Heterozygotes and wild-type showed no homocysteine change despite the same EGRac (erythrocyte glutathione reductase activation coefficient, a functional riboflavin test) improvement. This is a genotype-stratified randomized-trial finding, not a general-population effect.

Magnitude: Homocysteine fell 22% overall in TT homozygotes (16.1 to 12.5 µmol/L) and 40% when baseline riboflavin was low (22.0 to 13.2 µmol/L).

Blood Pressure Reduction in MTHFR 677TT Genotype ⚠️ Conflicted

Three Ulster RCTs in MTHFR 677TT adults reported systolic falls of about 6–13 mmHg at 1.6 mg daily, including 13/7 mmHg in treated cardiovascular patients (Horigan et al., 2010; Wilson et al., 2013). Wilson 2013 listed DSM Nutritional Products coauthors. Cochrane 2025 pooled four RCTs at −1.94 mmHg systolic, very low certainty (Bradbury et al., 2025). Genotype targeting versus mixed populations likely explains the split.

Magnitude: Targeted TT trials: about −6 to −13 mmHg systolic at 1.6 mg daily; Cochrane mixed-genotype pool: −1.94 mmHg systolic (95% confidence interval, CI, −5.74 to 1.86), very low certainty.

Low 🟩

Support of Hemoglobin When Iron Intake Is Limited

Riboflavin supports iron mobilization into hemoglobin. Adding it with retinol to iron-folate raised hemoglobin further in anemic pregnant women (Ma et al., 2008). A five-year Chinese cohort linked the highest intake quartile to about half the later anemia risk of the lowest (Shi et al., 2014).

Magnitude: Highest versus lowest intake quartile relative risk (RR) 0.52 (95% CI 0.28–0.98) for later anemia; a pregnancy trial of retinol plus riboflavin on iron-folate improved hemoglobin beyond iron-folate alone.

Lower Prevalence of Nuclear Cataract

In the Blue Mountains Eye Study, the highest versus lowest dietary riboflavin quintile had 50% lower odds of nuclear cataract after risk-factor adjustment (Cumming et al., 2000). These are cross-sectional food-frequency data, not a supplementation trial.

Magnitude: Odds ratio 0.5 (95% CI 0.3–0.9) for nuclear cataract, highest versus lowest dietary quintile.

Lower Colorectal Cancer Risk

A dose-response meta-analysis of 14 studies (14,934 cases) found higher vitamin B2 intake associated with lower colorectal-cancer risk (Ben et al., 2019). Residual confounding by overall diet quality is likely.

Magnitude: Pooled RR 0.87 (95% CI 0.81–0.93); about a 10% risk reduction as intake approached 5 mg/day.

Speculative 🟨

Mitochondrial Energy Capacity in Aging Tissue

Flavoproteins run electron transport and glutathione reductase. Aging tissues show lower mitochondrial capacity; whether extra riboflavin beyond repletion changes that trajectory is mechanistic only (Ashoori & Saedisomeolia, 2014).

Motor Function in Parkinson Disease

An open-label series using high-dose riboflavin plus red-meat restriction reported motor gains (Coimbra & Junqueira, 2003). Design, diet change, and later critique leave the signal anecdotal.

Benefit-Modifying Factors

  • MTHFR C677T genotype: TT homozygotes (often 10–30% of a population) show the homocysteine and blood-pressure responses; CC and CT genotypes do not, despite similar EGRac improvement (McNulty et al., 2006).

  • Baseline EGRac / riboflavin status: Homocysteine fell 40% when baseline status was poor versus 22% overall; replete adults gain little on one-carbon markers (folate–homocysteine metabolism) (McNulty et al., 2006).

  • Sex: Migraine is more prevalent in women of reproductive age, so that high-evidence use-case is concentrated there; the Ulster blood-pressure trials enrolled both sexes.

  • Pre-existing migraine or treated hypertension: Adult migraineurs are the population in which 400 mg was tested; blood-pressure signals were measured in already-treated hypertensives and cardiovascular patients with the TT genotype.

  • Age: Older adults more often have higher (worse) EGRac and lower pyridoxal 5’-phosphate when riboflavin is low, so repletion may matter more after 65 (Jarrett et al., 2022).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Yellow-Orange Urine (Chromaturia)

Unused riboflavin is excreted and colors urine bright yellow-orange. Reviews treat this as an expected, reversible marker of intake, not tissue injury, at ordinary supplement doses and at 400 mg (Thakur et al., 2017; Powers, 2003).

Magnitude: Occurs in essentially all people taking supplemental riboflavin; no associated organ injury is reported in available studies.

Low 🟥

Gastrointestinal Symptoms at High Dose

In the 55-person Schoenen trial, two riboflavin-arm events (diarrhea, polyuria / excess urine) and one placebo event (cramps) occurred; none was serious (Schoenen et al., 1998). Cochrane 2025 likewise found little difference in adverse events (2 versus 1 in the one trial that split them by arm) (Bradbury et al., 2025).

Magnitude: 2 events among riboflavin recipients versus 1 on placebo in Schoenen 1998; Cochrane: little to no difference in adverse events (low-certainty).

Speculative 🟨

Rare Hypersensitivity

Isolated hypersensitivity reports, including rare anaphylaxis to free riboflavin, exist. Randomized trials have not produced an incidence rate. The basis is case reports, not controlled data (Ou et al., 2001).

Cutaneous Photosensitivity at High Oral Doses

Riboflavin is the photosensitizer used in corneal cross-linking. Oral phototoxicity at 400 mg has not been shown in migraine trials; the concern is mechanistic only (Thakur et al., 2017).

Reduced Activity of Some Anthracycline Chemotherapy (Redox-Cycling Cancer Drugs)

High-dose antioxidant effects could, in principle, blunt redox-cycling drugs such as doxorubicin. This has not been shown in cancer RCTs and remains theoretical.

Risk-Modifying Factors

  • Transporter or kinase variants: Pathogenic SLC52A2/SLC52A3 (RFVT2/RFVT3) mutations cause riboflavin-transporter deficiency and raise, rather than lower, the need for high-dose riboflavin (Plantone et al., 2021).

  • Baseline status: Replete adults absorb little extra beyond the saturable ~25–27 mg window, so high-dose gastrointestinal effects are a high-dose phenomenon, not a repletion phenomenon.

  • Sex: No consistent sex difference in adverse-event rates appears in the adult migraine or Ulster blood-pressure trials.

  • Pre-existing gastrointestinal (GI) disease or photosensitizing therapy: Loose stool at 400 mg may matter more with active enteropathy (inflammatory or malabsorptive gut disease); photodynamic or anthracycline protocols are theoretical cautions.

  • Age: Older adults more often take multiple drugs that lower riboflavin status (see interactions); they do not show a unique toxicity signal.

Key Interactions & Contraindications

  • Probenecid (caution): Reduces renal riboflavin clearance; status rises and urine color deepens. No dose algorithm is established; monitoring EGRac is the practical check.

  • Anticholinergics (atropine, scopolamine) — monitor: Slowed gut motility can change saturable absorption. Separate timing if high-dose riboflavin is used for migraine.

  • Phenothiazines (chlorpromazine) and tricyclic antidepressants (amitriptyline) — monitor: May inhibit flavokinase (the enzyme that makes FMN from riboflavin) and lower FMN/FAD formation; EGRac can worsen despite intake.

  • Tetracyclines (doxycycline, tetracycline) — caution: Possible mutual reduction of absorption. Separate by at least 2 hours.

  • Barbiturates (phenobarbital, primidone) and heavy alcohol use — monitor: Increase turnover and lower status; repletion doses (not 400 mg) are the usual response.

  • Oral contraceptives (ethinyl estradiol) and thyroid hormone (levothyroxine) — monitor: Associated with lower riboflavin status; EGRac before attributing symptoms to the hormone.

  • Magnesium and coenzyme Q10 — potentiating (migraine): Combination products were tested (e.g., Gaul et al., 2015); additive mitochondrial support, not a safety clash.

  • Folate, vitamin B6, and vitamin B12 — potentiating (one-carbon): Riboflavin is the MTHFR and B6-activation cofactor; combinations are common in homocysteine protocols (Jarrett et al., 2022).

  • Iron — potentiating (anemia): Combined repletion outperformed iron-folate alone in pregnancy trials (Ma et al., 2008).

  • Anthracyclines (doxorubicin) — caution, theoretical: Antioxidant overlap; oncology review before high-dose use.

  • Over-the-counter analgesics and antacids (none identified): Contemporary monographs report no established clash with common nonprescription medicines; alcohol, listed above, is the main non-prescription drain on status.

Populations who should avoid Riboflavin:

  • Documented hypersensitivity to riboflavin
  • High-dose (hundreds of milligrams) use during active anthracycline chemotherapy unless the oncology team agrees

Risk Mitigation Strategies

  • Take with a large meal: Food more than quadruples absorption and lowers the chance of loose stool that appears when 400 mg is taken fasted.

  • Match dose to the use-case: 1.6–5 mg covers repletion and MTHFR work; reserve 400 mg for migraine to avoid unnecessary high-dose gastrointestinal symptoms.

  • Treat yellow urine as expected: Chromaturia is excretion, not hematuria (blood in the urine); it clears within 1–2 days after stopping and does not require evaluation if otherwise well.

  • Separate tetracyclines by 2 hours: Avoids the possible absorption clash without dropping either agent.

  • Sun and phototherapy caution at 400 mg: Limits theoretical cutaneous photosensitivity; extra unprotected ultraviolet light during a high-dose migraine trial is the setting of interest.

  • Recheck fluorescent assays if results clash with the clinic: Riboflavin fluorescence can perturb some urine tests; repeat off-supplement if the result will change a decision.

Therapeutic Protocol

  • Nutritional repletion: Adult Recommended Dietary Allowance (RDA) is 1.3 mg (men) and 1.1 mg (women); 5–25 mg daily is the usual correction band when EGRac is high.

  • MTHFR 677TT protocols (McNulty / Ulster): 1.6 mg daily for 12–16 weeks in the blood-pressure and homocysteine trials; OptiPREG uses 5 mg in pregnancy.

  • Migraine prophylaxis (Schoenen / American Academy of Neurology Level B): 400 mg once daily for at least 3 months, often with magnesium and coenzyme Q10; society members bill visits and prescriptions, not this vitamin.

  • Time of day: Morning with breakfast; late high doses have no sleep signal but meal timing drives absorption.

  • Half-life and splitting: Plasma half-life is about 1–2 hours; absorption saturates near 25–27 mg, so 400 mg is mostly unabsorbed. Trialists still used a single daily dose.

  • Genetics: MTHFR 677TT favors the 1.6–5 mg band; RFVT deficiency is a separate, high-dose specialty indication (Plantone et al., 2021).

  • Sex: No separate male/female milligram chart; migraine protocols enroll mostly women because migraine does.

  • Age: After 65, start with status testing; older adults more often need repletion, not 400 mg, unless migraine is the target.

  • Baseline biomarkers: EGRac, homocysteine, and (if hypertensive) MTHFR genotype steer dose better than a universal oral strength.

  • Conditions: Vegan or dairy-free diets, bariatric surgery, alcohol use, and hyperthyroidism raise repletion odds; pregnancy uses 1.4–1.6 mg RDA, not 400 mg, unless a headache specialist is directing care.

Discontinuation & Cycling

  • Duration of use: Repletion can be time-limited once EGRac is normal; migraine 400 mg and TT-genotype 1.6 mg are used as long as the indication lasts, not as a mandatory lifelong vitamin.

  • Withdrawal: No withdrawal syndrome is described; water-soluble stores run down over days to weeks.

  • Taper: Not used. Stopping is abrupt in the trials.

  • Cycling: Not used to preserve efficacy. Riboflavin is a cofactor, not a receptor agonist that down-regulates.

  • Washout of chromaturia: Yellow urine clears in about 1–2 days after the last dose.

Sourcing and Quality

  • Form: Plain riboflavin and riboflavin 5’-phosphate (FMN) both raise status; 5’-phosphate is often chosen when practitioners want the phosphorylated form, without a head-to-head outcome trial.

  • Third-party testing: U.S. Pharmacopeia (USP), NSF International, or ConsumerLab marks address overage and label claim; B-vitamin bottles often contain more than the label.

  • Tested examples: ConsumerLab’s B-vitamin review has approved standalone riboflavin (e.g., Vitacost 100 mg) and Thorne riboflavin 5’-phosphate; Life Extension sells its own 100 mg product (commercial interest).

  • Light and packaging: Riboflavin is light-sensitive; opaque bottles and dry storage matter more than brand story.

  • Meal pairing: A large meal is a quality step as much as a brand step — it is the main controllable absorption variable.

Practical Considerations

  • Time to effect: EGRac moves in days to a few weeks; homocysteine and blood pressure were measured at 12–16 weeks; migraine trials use a 3-month horizon before judging nonresponse.

  • Common pitfalls: Stopping at 4 weeks; using 400 mg when the goal is repletion; taking the dose fasted; ignoring MTHFR when the goal is homocysteine or blood pressure.

  • Regulatory status: Sold as a U.S. dietary supplement (Dietary Supplement Health and Education Act, DSHEA). The 400 mg migraine dose is a practitioner protocol, not a Food and Drug Administration (FDA) drug indication.

  • Cost and access: Inexpensive (typically well under $20/month even at 400 mg) and widely available; cost is not a barrier relative to prescription migraine preventives.

  • Payer incentives: Insurers and health systems spend far less on this vitamin than on calcitonin gene-related peptide (CGRP) monoclonal antibodies or add-on antihypertensives, a possible structural bias in how guidelines emphasize it.

Interaction with Foundational Habits

  • Sleep: No direct disruption or improvement is described. Indirect: fewer nocturnal migraine nights can improve sleep continuity after 2–3 months on 400 mg.

  • Nutrition: Direct and potentiating. Dairy, eggs, meat, and dark greens are the main food sources; vegans and dairy-free eaters run lower. Take the oral dose with a large meal. Alcohol lowers status.

  • Exercise: No hypertrophy-blunting signal. Indirect mitochondrial support only; no trial requires special peri-workout timing.

  • Stress management: No direct cortisol effect. Indirect: migraine and blood-pressure endpoints, if they move, reduce a physiologic stress load; this is not a stand-alone stress protocol.

Monitoring Protocol & Defining Success

Before starting, a functional riboflavin panel plus the one-carbon and blood-pressure context that the dose is meant to change gives a baseline. Typical pre-start work includes EGRac, plasma riboflavin if available, fasting homocysteine, and — when blood pressure or homocysteine is the goal — MTHFR C677T genotype. A migraine diary of monthly attack days is the outcome measure for the 400 mg protocol. Repeat EGRac and homocysteine at 8–12 weeks, then every 6–12 months once stable, with blood pressure at the same visits in TT-genotype users.

Ongoing monitoring uses those same timepoints rather than weekly labs. Yellow urine is expected and is not a stop rule. Success is a lower EGRac (toward ≤1.26), a homocysteine drop in TT homozygotes, fewer migraine days by month 3, or a blood-pressure change only if that was the planned target — not a universal “energy” score.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
EGRac ≤1.26 (optimal); 1.27–1.39 suboptimal; ≥1.40 deficient Functional riboflavin status Conventional labs often call <1.3 or <1.4 “adequate”; lower is better. Not a fasting test.
Plasma riboflavin No single longevity target; track rise from the person’s baseline Direct circulating vitamin Complements EGRac; less used than the activation coefficient.
Homocysteine Functional often <8–10 µmol/L; many labs flag only >15 One-carbon output, TT-genotype response Fasting preferred; pair with folate, B12, and B6 (pyridoxal 5’-phosphate).
MTHFR C677T TT versus CC/CT (genotype, not a range) Selects the 1.6–5 mg blood-pressure/homocysteine protocol Once-only genetic test.
Blood pressure Individual target; trial “goal” was ≤140/90 mmHg Endpoint in TT hypertension trials Same-arm, seated, repeated readings.
Hemoglobin / complete blood count Individual baseline; pregnancy often aims hemoglobin ≥110 g/L Anemia adjunct Relevant when iron intake is low.
Plasma pyridoxal 5’-phosphate (active vitamin B6) Conventional often >30 nmol/L; falls when EGRac is high Riboflavin-dependent B6 activation Pair with EGRac in older adults (Jarrett et al., 2022).
  • Migraine diary: Attack days, duration, and pain score each month for at least 3 months.
  • Energy and recovery: Subjective only; not a stand-alone success rule.
  • Urine color: Confirms intake; not a disease marker.
  • Skin, lips, and tongue: Resolution of cheilosis (cracked lip corners) or glossitis (inflamed tongue) if those were present at baseline.

Emerging Research

  • OptiPREG pregnancy blood-pressure trial: NCT04723836 (University of Ulster; DSM is a collaborator) randomizes MTHFR TT/CT pregnant women to 5 mg riboflavin, riboflavin plus 5-methyltetrahydrofolate (5-MTHF), or placebo (n=2,250; active, not recruiting). Could strengthen or weaken the genotype–blood-pressure claim.

  • Cochrane 2025 blood-pressure synthesis: Bradbury et al., 2025 already cut confidence in an untargeted blood-pressure use; larger genotype-restricted RCTs are the remaining test.

  • Inherited flavoprotein disease: Jaeger et al., 2026 systematically reviews high-dose riboflavin in inborn errors — a different population, but a window on what megadose flavin can and cannot rescue.

  • Migraine dose-response updates: Newer nutraceutical meta-analyses (Talandashti et al., 2025) keep 400 mg in the adult preventive set; a null modern RCT would move that High grade.

  • Neurologic mitochondrial modulation: Silva-Araújo et al., 2026 pools riboflavin’s mitochondrial story in neurologic disease; results could stay mechanistic or produce a new clinical signal.

Conclusion

Riboflavin is an inexpensive, water-soluble vitamin that the cell turns into two helper molecules used to make energy and to recycle the body’s main antioxidant. For a health-optimizing adult the evidence is strongest for fewer migraine attacks at high daily doses, with a clean safety record and only expected yellow urine and occasional digestive upset.

A separate story applies to people who carry two copies of a common change in the folate-processing enzyme that depends on this vitamin. In that group, low-milligram doses have lowered a blood waste marker linked to heart and vessel risk and, in some trials, blood pressure; a recent summary of those trials judged the blood-pressure claim very uncertain. Dietary intake tracks with lower rates of central lens clouding in the eye and large-bowel cancer in observational work, which cannot prove that an oral supplement will do the same.

The vitamin does not look like a general longevity drug. It looks like a low-risk lever for migraine, for people with that inherited enzyme change, and for anyone whose blood tests show the vitamin is running low. Some of the blood-pressure papers included authors from a vitamin manufacturer; the neurology and headache societies that rated high-dose use as probably effective bill visits and prescriptions, not this vitamin. Those conflicts are noted above and do not erase the independent migraine trials. No seller of the supplement is treated here as the last word.

Top - Benefits - Risks - Protocol